NASDAQ: INVAInnoviva Inc Stock
$19.05+0.13 (+0.69%)
Updated Dec 6, 2024
INVA Price
$19.05
Fair Value Price
N/A
Market Cap
$1.19B
52 Week Low
$14.33
52 Week High
$21.28
P/E
18.86x
P/B
1.78x
P/S
3.43x
PEG
N/A
Dividend Yield
N/A
Revenue
$352.75M
Earnings
$64.59M
Gross Margin
87.9%
Operating Margin
27.59%
Profit Margin
18.3%
Debt to Equity
0.84
Operating Cash Flow
$163M
Beta
0.77
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
INVA Overview
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine INVA's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
A
Value
C
Growth
C
Momentum
D
Sentiment
C
Safety
B
Financials
C
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
INVA
Ranked#44 of 554
Ranked#44 of 554
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $25.45 | A | |
| $6.72 | A | |
| $19.82 | A |
Be the first to know about important INVA news, forecast changes, insider trades & much more!
INVA News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how INVA scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
INVA was unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
INVA is good value based on its earnings relative to its share price (18.86x), compared to the US market average (29.86x)
P/E vs Market Valuation
INVA is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more INVA due diligence checks available for Premium users.
Valuation
INVA fair value
Fair Value of INVA stock based on Discounted Cash Flow (DCF)
Price
$19.05
Fair Value
$59.15
Undervalued by
67.79%
INVA was unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
INVA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
18.86x
Industry
-105.55x
Market
29.86x
INVA is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
INVA is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
INVA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.78x
Industry
5.68x
INVA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
INVA's financial health
Profit margin
Revenue
$89.5M
Net Income
$1.2M
Profit Margin
1.4%
INVA's Earnings (EBIT) of $97.31M... subscribe to Premium to read more.
Interest Coverage Financials
INVA's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.2B
Liabilities
$563.1M
Debt to equity
0.84
INVA's short-term assets ($400.62M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
INVA's short-term assets ($400.62M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
INVA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
INVA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$48.7M
Investing
-$5.3M
Financing
$211.0k
INVA's operating cash flow ($162.71M)... subscribe to Premium to read more.
Debt Coverage Financials
INVA vs Biotech Stocks
Innoviva Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.